Literature DB >> 30484263

Expression and Significance of TRIM 28 in Squamous Carcinoma of Esophagus.

Bo Liu1, Xiujuan Li2, Fengxi Liu2, Fengyu Li3, Shuxia Wei3, Junchao Liu1, Yang Lv4.   

Abstract

Tripartite motif-containing protein 28 (TRIM28) has been proved to accelerate cell proliferation and metastasis in a variety of human cancers. However, the role of TRIM28 in esophageal squamous cell carcinoma (ESCC) remains unclear. In this study, to compare the biological effect and significance of TRIM28 expression in ESCC, immunohistochemistry (streptavidin-perosidase, S-P) method was used firstly to examine the expression of TRIM28 in 136 cases of ESCC, 35 cases of high grade intraepithelial neoplasia (HGIN), 29 cases of low grade intraepithelial neoplasia (LGIN) and 37 cases of normal esophageal epithelium (NEE). Then the associations of TRIM28 expression with clinicopathological data and overall survival (OS) were also analyzed. Western blot was performed to evaluate TRIM28 protein in a total of 20 matched human ESCC and NEE tissues. Moreover, the localization of TRIM28 protein in ESCC and NEE tissues was also detected by immunofluorescence. TRIM28 protein was mainly distributed in the nucleus of ESCC. The expression of TRIM28 increased progressively from NEE to LGIN, to HGIN, and to ESCC, and it was also related to invasive depth, pTNM stage and lymph node metastasis in ESCC (P < 0.05). The results of western blot and immunofluorescence all showed that the relative expression of TRIM28 protein was markedly upregulated in ESCC compared with the NEE tissues (P < 0.01). However, prognostic analysis showed that TRIM28 may not be a prognostic factor of patients with ESCC. In conclusion, the overexpression of TRIM28 may play an important role for development and metastasis in ESCC.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; Immunofluorescence; Immunohistochemistry; Overall survival; TRIM28; Western blot

Mesh:

Substances:

Year:  2018        PMID: 30484263      PMCID: PMC6815281          DOI: 10.1007/s12253-018-0558-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  KAP-1, a novel corepressor for the highly conserved KRAB repression domain.

Authors:  J R Friedman; W J Fredericks; D E Jensen; D W Speicher; X P Huang; E G Neilson; F J Rauscher
Journal:  Genes Dev       Date:  1996-08-15       Impact factor: 11.361

2.  Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.

Authors:  Yu Song; Qisang Guo; Shujun Gao; Keqin Hua
Journal:  Biochem Biophys Res Commun       Date:  2018-03-16       Impact factor: 3.575

Review 3.  Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases.

Authors:  Liubov V Gushchina; Thomas A Kwiatkowski; Sayak Bhattacharya; Noah L Weisleder
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

4.  Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53.

Authors:  Jinjin Liu; Jun Rao; Xuming Lou; Jian Zhai; Zhenhua Ni; Xiongbiao Wang
Journal:  Cell Physiol Biochem       Date:  2017-11-09

Review 5.  TRIM proteins in cancer.

Authors:  Valeria Cambiaghi; Virginia Giuliani; Sara Lombardi; Cristiano Marinelli; Francesca Toffalorio; Pier Giuseppe Pelicci
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

6.  High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.

Authors:  Chunni Wang; Zitong Li; Fei Shao; Xueying Yang; Xiaoli Feng; Susheng Shi; Yibo Gao; Jie He
Journal:  J Exp Clin Cancer Res       Date:  2017-06-23

7.  TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway.

Authors:  Ye Sun; Bing Ji; Yifei Feng; Yue Zhang; Dongjian Ji; Chunyan Zhu; Sen Wang; Chuan Zhang; Dongsheng Zhang; Yueming Sun
Journal:  Oncol Rep       Date:  2017-05-22       Impact factor: 3.906

8.  TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.

Authors:  Hidetaka Kawabata; Kotaro Azuma; Kazuhiro Ikeda; Ikuko Sugitani; Keiichi Kinowaki; Takeshi Fujii; Akihiko Osaki; Toshiaki Saeki; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923

Review 9.  The complexity of TRIM28 contribution to cancer.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Maciej Wiznerowicz
Journal:  J Biomed Sci       Date:  2017-08-29       Impact factor: 8.410

Review 10.  TRIM proteins in blood cancers.

Authors:  Lisa J Crawford; Cliona K Johnston; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2017-11-06       Impact factor: 5.782

View more
  3 in total

Review 1.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

2.  A novel circRNA-miRNA-mRNA network revealed exosomal circ-ATP10A as a biomarker for multiple myeloma angiogenesis.

Authors:  Manya Yu; Jie Yu; Yanyu Zhang; Xiaoqi Sun; Runjie Sun; Mengting Xia; Sumei Li; Xing Cui
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 3.  Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class.

Authors:  Francesca D'Amico; Rishov Mukhopadhyay; Huib Ovaa; Monique P C Mulder
Journal:  Chembiochem       Date:  2021-03-18       Impact factor: 3.164

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.